All Guidance
Methylphenidate, Lisdexamfetamine, Dexamfetamine, Atomoxetine - For Attention Deficit Hyperactivity Disorder in adults aged over 17 years and in children and adolescents aged 6 to 17 years
Guanfacine - For Attention Deficit Hyperactivity Disorder in children and adolescents aged 6 to 17 years
LSCMMG has granted interim approval for this position statement ONLY. LSCMMG is aware that each locality, prior to the establishment of the ICB, had adopted the 'Over the counter items that should not be routinely prescribed in primary care policy'.
Interim approval has been granted to provide consistency of advice to prescribers whilst the ICB considers whether to adopt the 'Over the counter items that should not be routinely prescribed in primary care policy' across Lancashire and South Cumbria.
Amisulpride, Aripiprazole, Olanzapine, Quetiapine, Oral Risperidone
This shared prescribing guideline for the second-generation antipsychotic medications listed above has been developed with due consideration to the appropriate NICE Clinical Guidelines (CG) e.g. Bipolar Disorder (CG185), Psychosis and Schizophrenia in Children and Young People (CG155), Psychosis and Schizophrenia in Adults (CG178), Schizophrenia- Aripiprazole (TA213), Bipolar Disorder- Adolescents (TA292).
Please note: Morecambe Bay CCG has now adopted this Shared-care guideline for all areas, including South Cumbria.
Refer to Local Commissioning Policy Before Use
Treatment of Parkinson’s Disease
This guideline provides recommendations on the medical management of adults with chronic non-cancer pain.
Radiographic (Ankylosing Spondylitis) and Non-radiographic Axial Spondyloarthritis (ASp) LSCMMG Recommended Biologic Pathway
This guidance does not replace the SPC’s, which should be read in conjunction with this guidance.
Medical camouflaging products must only be initiated by a healthcare professional that specialises in skin colour matching and appropriate application techniques.
Please note: these products must only be continued in primary care if the patient’s GP believes issuing such a prescription will continue to significantly reduce the impact of the patient’s medical condition.
This guidance does not apply to the use of Sativex® (delta-9-etrahydrocannabinol and cannabidiol) oromucosal spray as an adjunct treatment for moderate to severe spasticity in multiple sclerosis
This guidance does not replace the SPC’s, which should be read in conjunction with this guidance.
NHS England has advised CCGs that a prescription for the treatment of infrequent constipation should not routinely be offered in primary care as the condition is appropriate for self-care. The NHS England guidance applies to short term, infrequent constipation caused by changes in lifestyle or diet such as lack of water or movement or changes in diet. GPs should continue to prescribe laxatives to manage acute constipation with more complex aetiology (e.g. iatrogenic) and chronic constipation.
The NHS England guidance does not apply to the management of children and laxatives for children should continue to be prescribed by GPs.